LLIN Evaluation in Uganda Project (LLINEUP2)
Primary Purpose
Malaria
Status
Completed
Phase
Not Applicable
Locations
Uganda
Study Type
Interventional
Intervention
long lasting insecticidal nets with alpha-cypermethrin + pyriproxyfen (PPF LLIN, Royal Guard))
long lasting insecticidal nets with deltamethrin + piperonyl butoxide (PBO LLIN, PermaNet 3.0))
Social behaviour change communication
Sponsored by
About this trial
This is an interventional prevention trial for Malaria focused on measuring long-lasting insecticidal net, pyriproxyfen, piperonyl butoxide, alpha-cypermethrin, deltamethrin
Eligibility Criteria
A) Primary outcome: All patients who present to the outpatient departments of the MRCs
B) Community surveys for secondary outcomes:
Inclusion Criteria:
- At least one adult aged 18 years or older present
- Adult is a usual resident who slept in the sampled household on the night before the survey
- Agreement of the adult resident to provide informed consent for the household survey
Exclusion Criteria:
- Dwelling destroyed or not found
- Household vacant
- No adult resident home on more than 3 occasions
Sites / Locations
- Infectious Diseases Research Collaboration
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Royal Guard
PermaNet 3.0
Arm Description
alpha-cypermethrin + pyriproxyfen (PPF)
deltamethrin + piperonyl butoxide (PBO)
Outcomes
Primary Outcome Measures
Malaria incidence
Number of cases of laboratory-confirmed malaria diagnosed at the MRC among patients residing in the catchment areas per unit time/the population of the catchment areas
Secondary Outcome Measures
Prevalence of parasitaemia
Proportion of blood smears positive for parasites by microscopy in children aged 2-10 years at the time of cross-sectional surveys
Prevalence of parasitaemia
Proportion of blood smears positive for parasites by microscopy in children aged 2-10 years at the time of cross-sectional surveys
Prevalence of anaemia
Proportion of children aged 2-4 years with haemoglobin < 11 g/dL at the time of cross-sectional surveys
Prevalence of anaemia
Proportion of children aged 2-4 years with haemoglobin < 11 g/dL at the time of cross-sectional surveys
Proportion of households that owned at least one LLIN
Proportion of households with at least one LLIN at the time of cross-sectional surveys
Proportion of households that owned at least one LLIN
Proportion of households with at least one LLIN at the time of cross-sectional surveys
Proportion of households that owned at least one LLIN for every two occupants
Proportion of households with at least one LLIN per every two occupants at the time of cross-sectional surveys
Proportion of households that owned at least one LLIN for every two occupants
Proportion of households with at least one LLIN per every two occupants at the time of cross-sectional surveys
Proportion of household residents who slept under an LLIN the previous night
Proportion of households residents who report sleeping under LLIN the previous night at the time of cross-sectional surveys
Proportion of household residents who slept under an LLIN the previous night
Proportion of households residents who report sleeping under LLIN the previous night at the time of cross-sectional surveys
Incremental cost-effectiveness ratios
USD per disability-adjusted life year adverted and per malaria case adverted
Full Information
NCT ID
NCT04566510
First Posted
September 22, 2020
Last Updated
May 11, 2023
Sponsor
University of California, San Francisco
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
1. Study Identification
Unique Protocol Identification Number
NCT04566510
Brief Title
LLIN Evaluation in Uganda Project
Acronym
LLINEUP2
Official Title
Impact of Long-lasting Insecticidal Nets (LLINs) Treated With Pyrethroid Plus Pyriproxyfen vs LLINs Treated With Pyrethroid Plus Piperonyl Butoxide on Malaria Incidence in Uganda: a Cluster-randomised Trial
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
October 17, 2020 (Actual)
Primary Completion Date
March 31, 2023 (Actual)
Study Completion Date
March 31, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
In Uganda, the National Malaria Control Division (NMCD) and implementing partners plan to deliver long-lasting insecticidal nets (LLINs) nationwide in 2020-21, through a mass distribution campaign supported by generous contributions from international donors. LLINs will be distributed free-of-charge to all Ugandan households, aiming to achieve universal coverage. The Against Malaria Foundation has agreed to provide LLINs treated with a pyrethroid insecticide plus pyriproxyfen (PPF) (Royal Guard, Disease Control Technology) and LLINs treated with a pyrethroid insecticide plus piperonyl butoxide (PBO) (PermaNet 3.0, Vestergaard), presenting an opportunity to rigorously evaluate and compare these two LLINs at scale across Uganda. In collaboration with the MOH, the investigators propose to embed a cluster-randomised trial to compare the impact of LLINs with PPF to LLINs with PBO into Uganda's 2020 LLIN distribution campaign. The primary objective of the study is: To evaluate the impact of LLINs treated with a pyrethroid insecticide plus pyriproxyfen (PPF LLINs), as compared to LLINs treated with a pyrethroid plus piperonyl butoxide (PBO LLINs), on malaria incidence in Uganda. The study will test the hypothesis that malaria incidence will be lower in intervention clusters (randomised to receive PPF LLINs) than in control clusters (randomised to receive PBO LLINs).
Detailed Description
This rigorous, cluster-randomised trial will evaluate the impact of long-lasting insecticidal nets (LLINs) distributed in Uganda through the 2020-21 national universal coverage campaign. A cluster has been defined as the catchment area of a Malaria Reference Centre (MRC). A total of 64 clusters have been included in the study, covering 32 high malaria burden districts in Uganda where IRS is not being implemented. Clusters have been randomised in a 1:1 ratio in blocks of two by district to receive one of two types of LLINs: (1) pyriproxyfen (PPF) LLINs (Royal Guard) [n=32] and (2) piperonyl butoxide (PBO) LLINs (PermaNet 3.0) [n=32].
The intervention, including delivery of the LLINs and social and behaviour change communication (SBCC), will be led by the Ugandan National Malaria Control Division (NMCD) and other stakeholders. Currently, LLINs are scheduled to be delivered in the study areas from October 2020 to January 2021. The evaluation will include health facility surveillance at the MRCs to generate continuous estimates of malaria incidence for each MRC catchment area, cross-sectional community surveys at baseline (if additional resources are available), and at 12- and 24-months after LLIN distribution to gather information on net survivorship and use, and parasite prevalence in children 2-10 years of age, entomology surveys, and assessment of net durability and efficacy. The primary outcome of the trial will be malaria incidence as estimated using the health facility surveillance.
For each cluster the study will use a 'fried egg' approach for delivering the intervention ('egg white') and measuring our outcomes ('egg yolk'). The 'white' of the egg will include one sub-county per cluster, where the MRC is located. PPF LLINs and PBO LLINs will be distributed to the designated sub-county, as allocated in the randomisation. The 'yolk' of the egg will be the catchment area directly surrounding each MRC, where care-seeking at the MRC is expected to be high (i.e. if someone within the catchment area develops malaria, they are likely to seek care at the MRC). To determine the population of the MRC catchment areas, and to generate a sampling frame for the community surveys, the investigators will do the following: (1) define the catchment area of each MRC before the onset of the trial using data on village of residence from patients attending the MRCs, (2) map and enumerate all households within the MRC catchment areas before the 12-month community survey, and (3) conduct a census survey within each MRC catchment area to generate an accurate estimate of the study population in which study outcomes will be measured concurrently with the 12-month community survey.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malaria
Keywords
long-lasting insecticidal net, pyriproxyfen, piperonyl butoxide, alpha-cypermethrin, deltamethrin
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
cluster-randomised trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
217086 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Royal Guard
Arm Type
Experimental
Arm Description
alpha-cypermethrin + pyriproxyfen (PPF)
Arm Title
PermaNet 3.0
Arm Type
Active Comparator
Arm Description
deltamethrin + piperonyl butoxide (PBO)
Intervention Type
Other
Intervention Name(s)
long lasting insecticidal nets with alpha-cypermethrin + pyriproxyfen (PPF LLIN, Royal Guard))
Intervention Description
Next-generation bed net combining insecticides with different modes of action
Intervention Type
Other
Intervention Name(s)
long lasting insecticidal nets with deltamethrin + piperonyl butoxide (PBO LLIN, PermaNet 3.0))
Intervention Description
Next-generation bed net combining an insecticide with a synergist
Intervention Type
Behavioral
Intervention Name(s)
Social behaviour change communication
Intervention Description
SBCC activities will use digital and other platforms, similar to those used for the COVID-19 response, including the following: (1) LLIN launch on television and radio; (2) regional advocacy meetings on Zoom; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about COVID-19, malaria, and use, care, repair and repurposing of LLINs.
Primary Outcome Measure Information:
Title
Malaria incidence
Description
Number of cases of laboratory-confirmed malaria diagnosed at the MRC among patients residing in the catchment areas per unit time/the population of the catchment areas
Time Frame
24 months following LLIN distribution
Secondary Outcome Measure Information:
Title
Prevalence of parasitaemia
Description
Proportion of blood smears positive for parasites by microscopy in children aged 2-10 years at the time of cross-sectional surveys
Time Frame
12 months following LLIN distribution
Title
Prevalence of parasitaemia
Description
Proportion of blood smears positive for parasites by microscopy in children aged 2-10 years at the time of cross-sectional surveys
Time Frame
24 months following LLIN distribution
Title
Prevalence of anaemia
Description
Proportion of children aged 2-4 years with haemoglobin < 11 g/dL at the time of cross-sectional surveys
Time Frame
12 months following LLIN distribution
Title
Prevalence of anaemia
Description
Proportion of children aged 2-4 years with haemoglobin < 11 g/dL at the time of cross-sectional surveys
Time Frame
24 months following LLIN distribution
Title
Proportion of households that owned at least one LLIN
Description
Proportion of households with at least one LLIN at the time of cross-sectional surveys
Time Frame
12 months following LLIN distribution
Title
Proportion of households that owned at least one LLIN
Description
Proportion of households with at least one LLIN at the time of cross-sectional surveys
Time Frame
24 months following LLIN distribution
Title
Proportion of households that owned at least one LLIN for every two occupants
Description
Proportion of households with at least one LLIN per every two occupants at the time of cross-sectional surveys
Time Frame
12 months following LLIN distribution
Title
Proportion of households that owned at least one LLIN for every two occupants
Description
Proportion of households with at least one LLIN per every two occupants at the time of cross-sectional surveys
Time Frame
24 months following LLIN distribution
Title
Proportion of household residents who slept under an LLIN the previous night
Description
Proportion of households residents who report sleeping under LLIN the previous night at the time of cross-sectional surveys
Time Frame
12 months following LLIN distribution
Title
Proportion of household residents who slept under an LLIN the previous night
Description
Proportion of households residents who report sleeping under LLIN the previous night at the time of cross-sectional surveys
Time Frame
24 months following LLIN distribution
Title
Incremental cost-effectiveness ratios
Description
USD per disability-adjusted life year adverted and per malaria case adverted
Time Frame
24 months following LLIN distribution
10. Eligibility
Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
A) Primary outcome: All patients who present to the outpatient departments of the MRCs
B) Community surveys for secondary outcomes:
Inclusion Criteria:
At least one adult aged 18 years or older present
Adult is a usual resident who slept in the sampled household on the night before the survey
Agreement of the adult resident to provide informed consent for the household survey
Exclusion Criteria:
Dwelling destroyed or not found
Household vacant
No adult resident home on more than 3 occasions
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sarah Staedke, MD, PhD
Organizational Affiliation
London School of Hygiene and Tropical Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Moses Kamya, MBChB, MMed, PhD
Organizational Affiliation
Infectious Diseases Research Collaboration
Official's Role
Principal Investigator
Facility Information:
Facility Name
Infectious Diseases Research Collaboration
City
Kampala
Country
Uganda
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
LLIN Evaluation in Uganda Project
We'll reach out to this number within 24 hrs